





(1.02),




(2.03),




(2.04),




(2.05),




(2.06),




(1.03),




(1.1),



(2.01),




(2.07), and




(2.02).


7. A compound according to any one of claims 1 to 6, which is




(1.02),




(2.03),




(2.04),




(2.05),




(2.06),




(1.03),




(1.1),



(2.01),



(2.07), and



(2.02).

8. A method of synthesising a pharmaceutically acceptable salt of the compounds according to claim 7 wherein the parent compound, which contains a cationic group, is reacted by conventional chemical methods.

9. A method of synthesising a pharmaceutically acceptable salt of the compounds according to claim 8 wherein the parent compound, which contains a cationic group, is reacted with a sufficient amount of the appropriate base or acid in water or an organic diluent.

10. A pharmaceutically acceptable salt of the parent compound of compound (1.02) according to claim 7.

11. A pharmaceutically acceptable salt of the parent compound of compound (2.03) according to claim 7.

12. A pharmaceutically acceptable salt of the parent compound of compound (2.04) according to claim 7.

13. A pharmaceutically acceptable salt of the parent compound of compound (2.05) according to claim 7.

14. A pharmaceutically acceptable salt of the parent compound of compound (2.06) according to claim 7.

15. A pharmaceutically acceptable salt of the parent compound of compound (1.03)

according to claim 7.

16. A pharmaceutically acceptable salt of the parent compound of compound (1.1) according to claim 7.

17. A pharmaceutically acceptable salt of the parent compound of compound (2.01) according to claim 7.

18. A pharmaceutically acceptable salt of the parent compound of compound (2.07) according to claim 7.

19. A pharmaceutically acceptable salt of the parent compound of compound (2.02) according to claim 7.

20. A compound according to one or more of claims 1 to 7 or a pharmaceutically acceptable salt thereof for use as a medicament.

21. A compound according to one or more of claims 1 to 7 or a pharmaceutically acceptable salt thereof for use in the treatment of a disease selected from among respiratory diseases or complaints and allergic diseases of the airways.

22. A compound according to one or more of claims 1 to 7 or a pharmaceutically acceptable salt thereof for use in the treatment of a disease selected from among chronic bronchitis, acute bronchitis, bronchitis caused by bacterial or viral infection or fungi or helminths, allergic bronchitis, toxic bronchitis, chronic obstructive bronchitis (COPD), asthma, paediatric asthma, bronchiectasis, allergic alveolitis, allergic or non-allergic rhinitis, chronic sinusitis, idiopathic pulmonary fibrosis, cystic fibrosis or mucoviscidosis, alpha-1-antitrypsin deficiency, cough, pulmonary emphysema, interstitial lung diseases, alveolitis, hyperreactive airways, nasal polyps, pulmonary oedema, pneumonitis of

different origins, and dry eyes.

23. A pharmaceutical composition comprising at least one compound according to one or more of claims 1 to 7 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

24. Medicament combination which contains, besides one or more compounds according to one or more of claims 1 to 7 or a pharmaceutically acceptable salt thereof, as further active substances, one or more compounds selected from among the categories of further ENaC inhibitors, betamimetics, anticholinergics, corticosteroids, PDE4-inhibitors, LTD4-antagonists, EGFR-inhibitors, dopamine agonists, H1-antihistamines, PAF-antagonists, MAP-kinase inhibitors, MPR4-Inhibitors, iNOS-Inhibitors, SYK-Inhibitors, correctors of the cystic fibrosis transmembrane regulator (CFTR) and CFTR potentiators or double or triple combinations thereof.